Published in Mol Endocrinol on May 08, 2008
VENNTURE--a novel Venn diagram investigational tool for multiple pharmacological dataset analysis. PLoS One (2012) 1.36
Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. J Clin Endocrinol Metab (2010) 1.02
GABAergic transmission to gonadotropin-releasing hormone (GnRH) neurons is regulated by GnRH in a concentration-dependent manner engaging multiple signaling pathways. J Neurosci (2009) 0.95
Gonadotropin-releasing hormone receptor system: modulatory role in aging and neurodegeneration. CNS Neurol Disord Drug Targets (2010) 0.84
Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function. Mol Cell Endocrinol (2010) 0.82
Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists. Mol Endocrinol (2009) 0.79
Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent. J Mol Biochem (2012) 0.75
Exploring 3D structure of human gonadotropin hormone receptor at antagonist state using homology modeling, molecular dynamic simulation, and cross-docking studies. J Mol Model (2016) 0.75
Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc Natl Acad Sci U S A (2006) 4.33
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer (2005) 3.56
The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem (2000) 2.44
Gonadotropin-releasing hormone receptors. Endocr Rev (2004) 2.22
Hypothalamic hormones and cancer. Front Neuroendocrinol (2001) 1.61
Gonadotropin-releasing hormone and its analogs. Annu Rev Med (1994) 1.61
Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev (1986) 1.56
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature (1985) 1.53
Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem (2003) 1.51
Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab (2000) 1.49
Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev (1997) 1.39
Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev (1997) 1.37
Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev (2004) 1.36
Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab (1987) 1.27
Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science (1985) 1.24
Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet (1982) 1.20
Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev (2005) 1.08
Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res (2004) 1.08
LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs (2001) 1.07
GnRH II and type II GnRH receptors. Trends Endocrinol Metab (2003) 1.06
Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor. J Biol Chem (2007) 1.02
Gonadotropin-releasing hormone receptors with intracellular carboxyl-terminal tails undergo acute desensitization of total inositol phosphate production and exhibit accelerated internalization kinetics. J Biol Chem (1998) 1.02
GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer (2003) 1.01
The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol (2003) 1.00
Glutamate 301 of the mouse gonadotropin-releasing hormone receptor confers specificity for arginine 8 of mammalian gonadotropin-releasing hormone. J Biol Chem (1994) 1.00
Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol (2002) 1.00
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol (2004) 0.94
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology (2001) 0.94
Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction. Biochemistry (2000) 0.93
Asn102 of the gonadotropin-releasing hormone receptor is a critical determinant of potency for agonists containing C-terminal glycinamide. J Biol Chem (1996) 0.92
The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology (1999) 0.91
Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. Am J Obstet Gynecol (1994) 0.90
Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy. Neuroendocrinology (2008) 0.89
A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. Endocrinology (1998) 0.88
Type II gonadotrophin-releasing hormone (GnRH-II) in reproductive biology. Reproduction (2003) 0.87
Conformational energy analysis of the molecule, luteinizing hormone-releasing hormone. 2. Tetrapeptide and decapeptide analogues. J Am Chem Soc (1976) 0.87
Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res (1991) 0.86
Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab (2004) 0.85
A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology (2003) 0.84
Design of potent cyclic gonadotropin releasing hormone antagonists. J Med Chem (1988) 0.84
Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett (2005) 0.84
Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci U S A (1992) 0.84
The DRY motif as a molecular switch of the human oxytocin receptor. Biochemistry (2005) 0.83
Signaling and antiproliferative effects mediated by GnRH receptors after expression in breast cancer cells using recombinant adenovirus. Endocrinology (2001) 0.83
Role of aspartate7.32(302) of the human gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation. Mol Pharmacol (2001) 0.82
Gonadotropin-releasing hormone receptor-mediated growth suppression of immortalized LbetaT2 gonadotrope and stable HEK293 cell lines. Endocrinology (2003) 0.82
Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol Endocrinol (2000) 0.82
Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Adv Drug Deliv Rev (1997) 0.81
The genes encoding the type II gonadotropin-releasing hormone receptor and the ribonucleoprotein RBM8A in humans overlap in two genomic loci. Genomics (2001) 0.81
Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab (1996) 0.81
Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res (1999) 0.80
Evolution of constrained gonadotropin-releasing hormone ligand conformation and receptor selectivity. J Biol Chem (2005) 0.80
Identification of a novel ligand binding residue Arg38(1.35) in the human gonadotropin-releasing hormone receptor. Mol Pharmacol (2007) 0.79
Outside-in and inside-out signaling: the new concept that selectivity of ligand binding at the gonadotropin-releasing hormone receptor is modulated by the intracellular environment. Endocrinology (2004) 0.79
Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res (2004) 0.79
Conformational constraint of mammalian, chicken, and salmon GnRHs, but not GnRH II, enhances binding at mammalian and nonmammalian receptors: evidence for preconfiguration of GnRH II. Mol Endocrinol (2002) 0.79
Conformational analysis of a highly potent dicyclic gonadotropin-releasing hormone antagonist by nuclear magnetic resonance and molecular dynamics. J Med Chem (1993) 0.78
Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets (2006) 0.78
Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, and cationic effects. J Clin Endocrinol Metab (1985) 0.78
Conserved amino acid residues that are important for ligand binding in the type I gonadotropin-releasing hormone (GnRH) receptor are required for high potency of GnRH II at the type II GnRH receptor. Mol Endocrinol (2006) 0.76
Rapid desensitization of GnRH-stimulated intracellular signalling events in alpha T3-1 and HEK-293 cells expressing the GnRH receptor. Endocrinology (1995) 0.76
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry (2006) 3.35
The Concise Guide to PHARMACOLOGY 2013/14: ion channels. Br J Pharmacol (2013) 3.03
Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol Med (2006) 2.79
BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci (2004) 2.76
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
"Control" laboratory rodents are metabolically morbid: why it matters. Proc Natl Acad Sci U S A (2010) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med (2006) 2.32
The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol (2013) 2.29
Gonadotropin-releasing hormone receptors. Endocr Rev (2004) 2.22
The Concise Guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol (2013) 2.07
Discovery of potent kisspeptin antagonists delineate physiological mechanisms of gonadotropin regulation. J Neurosci (2009) 2.07
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol (2007) 2.04
Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol (2010) 2.02
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
What sleep characteristics predict cognitive decline in the elderly? Sleep Med (2012) 1.96
Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev (2006) 1.94
Reliability and comparability of psychosis patients' retrospective reports of childhood abuse. Schizophr Bull (2009) 1.94
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol (2013) 1.88
Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus (2009) 1.84
Insomnia and health-related quality of life. Sleep Med Rev (2009) 1.79
Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev (2012) 1.76
Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med (2009) 1.74
Self-harm in first-episode psychosis. Br J Psychiatry (2008) 1.72
The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol (2013) 1.70
Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J (2013) 1.69
A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev (2004) 1.68
Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med (2012) 1.68
IUPHAR-DB: updated database content and new features. Nucleic Acids Res (2012) 1.66
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res (2010) 1.65
Parental separation, loss and psychosis in different ethnic groups: a case-control study. Psychol Med (2007) 1.64
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev (2013) 1.60
Sex-dependent metabolic, neuroendocrine, and cognitive responses to dietary energy restriction and excess. Endocrinology (2007) 1.59
An evolutionarily conserved form of gonadotropin-releasing hormone coordinates energy and reproductive behavior. Endocrinology (2003) 1.57
The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr (2013) 1.56
Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease. Hum Mutat (2006) 1.53
Clinical and social determinants of duration of untreated psychosis in the AESOP first-episode psychosis study. Br J Psychiatry (2006) 1.53
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res (2007) 1.49
Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes (2008) 1.42
Kisspeptin signalling in the hypothalamic arcuate nucleus regulates GnRH pulse generator frequency in the rat. PLoS One (2009) 1.42
First episode psychosis and ethnicity: initial findings from the AESOP study. World Psychiatry (2006) 1.39
Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci (2006) 1.36
VENNTURE--a novel Venn diagram investigational tool for multiple pharmacological dataset analysis. PLoS One (2012) 1.36
Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer (2005) 1.32
Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS One (2010) 1.32
Gender differences in the association between childhood abuse and psychosis. Br J Psychiatry (2009) 1.30
Potent action of RFamide-related peptide-3 on pituitary gonadotropes indicative of a hypophysiotropic role in the negative regulation of gonadotropin secretion. Endocrinology (2008) 1.28
PTEN is destabilized by phosphorylation on Thr366. Biochem J (2007) 1.28
Kisspeptin is essential for the full preovulatory LH surge and stimulates GnRH release from the isolated ovine median eminence. Endocrinology (2011) 1.27
Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells. Diabetes (2011) 1.26
Identification of human GnIH homologs, RFRP-1 and RFRP-3, and the cognate receptor, GPR147 in the human hypothalamic pituitary axis. PLoS One (2009) 1.25
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J Pathol (2012) 1.24
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res (2002) 1.24
Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell (2013) 1.23
Hippocampal gene expression patterns underlying the enhancement of memory by running in aged mice. Neurobiol Aging (2008) 1.22
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab (2007) 1.22
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr Relat Cancer (2006) 1.21
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res (2002) 1.20
Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry (2009) 1.20
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res (2005) 1.19
No pain, no gain: an exploratory within-subjects mixed-methods evaluation of the patient experience of sleep restriction therapy (SRT) for insomnia. Sleep Med (2011) 1.19
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res (2012) 1.19
Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol (2003) 1.17
Prokineticin 1 signaling and gene regulation in early human pregnancy. Endocrinology (2008) 1.17
iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease. PLoS One (2008) 1.16
Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression. Diabetes (2010) 1.16
PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci Signal (2012) 1.15
Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther (2009) 1.15
Impact of reduced meal frequency without caloric restriction on glucose regulation in healthy, normal-weight middle-aged men and women. Metabolism (2007) 1.13
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res (2007) 1.12
Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci (2009) 1.12
Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications. Neuroendocrinology (2012) 1.12
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol (2007) 1.11
Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin Cancer Res (2002) 1.11
Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab (2002) 1.11
A functional magnetic resonance imaging study of overt letter verbal fluency using a clustered acquisition sequence: greater anterior cingulate activation with increased task demand. Neuroimage (2002) 1.10
Potential roles of the prokineticins in reproduction. Trends Endocrinol Metab (2007) 1.10
Duration of untreated psychosis and ethnicity in the AESOP first-onset psychosis study. Psychol Med (2005) 1.09
Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet (2010) 1.08
New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev (2012) 1.08
Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res (2004) 1.08
VennPlex--a novel Venn diagram program for comparing and visualizing datasets with differentially regulated datapoints. PLoS One (2013) 1.08